GlassScriptPhysician profile
Brian J Davis
NPI 1437199346
$4,879.25
in general payments reported to CMS, 2019-2025
46 companies · $729 in 2025
The $729 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,218 · 2020: $676 · 2021: $644 · 2022: $566 · 2023: $566 · 2024: $480 · 2025: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,774.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $652.66 | 2019-2024 | |
| Abbvie INC. | $442.26 | 2021-2025 | Vraylar |
| Novo Nordisk INC | $423.85 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $327.09 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $301.70 | 2019-2025 | Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $243.88 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Allergan, INC. | $217.54 | 2019-2020 | |
| Abbott Laboratories | $213.18 | 2021-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $210.36 | 2019 | |
| Lilly USA, LLC | $208.97 | 2019-2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $183.05 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $154.81 | 2019-2024 | Verquvo, Belsomra, Capvaxive |
| Sanofi-Aventis U.S. LLC | $124.62 | 2019-2025 | |
| Tandem Diabetes Care, INC. | $115.89 | 2019 | |
| Insulet Corporation | $98.40 | 2023-2024 | Omnipod |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.